GO:0010719 negative regulation of epithelial to mesenchymal transition: Suppression Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010719 describes any process that decreases the rate, frequency, or extent of epithelial to mesenchymal transition (EMT), a developmental and pathological program in which epithelial cells lose polarity and acquire migratory mesenchymal traits.
• Negative regulation of EMT is essential for maintaining tissue architecture and preventing fibrosis and cancer metastasis; its loss is associated with aggressive tumors and poor prognosis.
• Key molecular players include microRNAs (e.g., miR-424, miR-93), epigenetic modifiers (e.g., SMYD5), and signaling pathways such as TGF-beta and inflammatory cytokine cascades.
• Epigenetic regulation, including histone methylation and DNA methylation, is a central mechanism for suppressing EMT and cancer stem cell generation.
• Experimental models for studying negative regulation of EMT include CRISPR knockout, point mutation, knock-in, and overexpression cell lines, combined with RNA-seq, proteomics, and imaging.
• The term is a biological process annotation; its disruption contributes to breast cancer, lung cancer, and fibrotic diseases, making it a target for therapeutic intervention.
Description
Epithelial to mesenchymal transition (EMT) is a fundamental cellular program that converts adherent epithelial cells into motile mesenchymal cells, and it is tightly controlled during embryogenesis and wound healing. The Gene Ontology term GO:0010719, negative regulation of epithelial to mesenchymal transition, captures all processes that decrease the rate, frequency, or extent of EMT. This regulatory term is critical because unchecked EMT drives pathological conditions such as cancer metastasis and organ fibrosis. Understanding how EMT is negatively regulated provides insights into tumor suppression and tissue homeostasis. Researchers study this process using a variety of molecular and cellular approaches, including CRISPR-based genome editing, to identify and validate suppressors of EMT. The importance of this term is underscored by the many signaling pathways and epigenetic modifiers that converge to inhibit EMT, offering potential therapeutic targets.
negative regulation of epithelial to mesenchymal transition At A Glance
| GO ID | GO:0010719 |
|---|---|
| GO term | negative regulation of epithelial to mesenchymal transition |
| Ontology | biological_process |
| Synonym | none |
| Major function | Suppression of the epithelial to mesenchymal transition program, maintaining epithelial cell phenotype and preventing mesenchymal transformation. |
| Related processes | Regulation of cell adhesion, cell polarity, extracellular matrix remodeling, and transcriptional repression. |
| Key regulators | MicroRNAs (miR-424, miR-93), epigenetic enzymes (SMYD5), and signaling molecules (SH2B3). |
| Disease relevance | Cancer progression, fibrosis, and developmental disorders. |
What Is GO:0010719?
GO:0010719 is a biological process term defined as any process that decreases the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition is a process where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components, and becomes a migratory mesenchymal cell. Thus, negative regulation of EMT encompasses molecular events that block or reverse these phenotypic changes, such as transcriptional repression of mesenchymal genes, stabilization of epithelial adhesion complexes, or epigenetic silencing of EMT-inducing factors.
Why Is negative regulation of epithelial to mesenchymal transition Important in Cell Biology?
Negative regulation of EMT is vital for preserving tissue integrity and preventing the onset of metastasis. Loss of this regulation leads to enhanced cell migration, invasion, and resistance to apoptosis, which are hallmarks of aggressive cancers. Moreover, epigenetic and microRNA-mediated suppression of EMT can reverse the mesenchymal phenotype, offering a strategy for therapeutic intervention. Understanding the mechanisms that negatively regulate EMT is therefore essential for developing targeted therapies against cancer and fibrotic diseases.
• Prevents cancer metastasis by inhibiting epithelial cells from acquiring migratory and invasive properties.
• Maintains tissue homeostasis and proper organ architecture during development and adulthood.
• Counteracts fibrosis by blocking myofibroblast differentiation and extracellular matrix deposition.
• Regulates cancer stem cell generation, which is linked to tumor recurrence and therapy resistance.
• Serves as a target for epigenetic drugs that can reverse EMT in triple-negative breast cancer.
• MicroRNAs such as miR-93 and miR-424 act as negative regulators of EMT, providing biomarkers and therapeutic candidates.
• Dysregulation of negative regulators like SH2B3 contributes to lung cancer progression.
• Inflammatory cytokines can induce EMT, and negative regulation by epigenetic mechanisms is crucial to counterbalance this.
• Dietary compounds such as galangin can modulate epigenetic enzymes to reverse EMT, highlighting nutraceutical potential.
• Studying negative regulation of EMT aids in understanding developmental processes like somitogenesis.
What Happens During negative regulation of epithelial to mesenchymal transition?
Transcriptional repression of EMT-inducing factors
In simple terms: The cell blocks the production of proteins that would normally drive EMT.
Negative regulation of EMT often involves transcriptional repression of master regulators such as SNAI1, TWIST1, and ZEB1. For example, SNAI1-mediated transcriptional regulation of EMT genes in breast cancer stem cells can be counteracted by repressors that inhibit SNAI1 expression or activity. Epigenetic modifications, such as histone deacetylation and DNA methylation, contribute to silencing these EMT-inducing genes.
MicroRNA-mediated inhibition
In simple terms: Small RNA molecules interfere with the messages that produce EMT proteins.
MicroRNAs (miRNAs) can directly target mRNAs encoding EMT transcription factors or signaling components. miR-424 regulates myofibroblast differentiation during EMT, acting as a negative regulator. Similarly, miR-93 affects EMT and vasculogenic mimicry in triple-negative breast cancer cells, and its modulation can suppress mesenchymal traits. These miRNAs provide a layer of post-transcriptional control that decreases EMT extent.
Epigenetic silencing of mesenchymal genes
In simple terms: Chemical tags on DNA or histones keep EMT genes turned off.
Epigenetic enzymes such as SMYD5 mediate negative regulation of SH2B3, which in turn controls EMT in lung cancer. Inflammatory cytokine-induced EMT and cancer stem cell generation are subject to epigenetic regulation, including histone methylation and acetylation. Dietary flavonoids like galangin, in combination with SAHA, can reverse EMT through epigenetic modulations in triple-negative breast cancer.
Stabilization of epithelial cell adhesion and polarity
In simple terms: The cell reinforces its connections to neighbors and its top-bottom orientation.
Negative regulation of EMT includes processes that maintain E-cadherin-mediated adherens junctions and apical-basal polarity. Loss of these features is a hallmark of EMT, so their preservation or restoration opposes the transition. Signaling pathways that strengthen cell-cell adhesion can thus be considered negative regulators of EMT.
Inhibition of EMT-inducing signaling pathways
In simple terms: The cell dampens signals that tell it to become mesenchymal.
TGF-beta, inflammatory cytokines, and myostatin can promote EMT, and negative regulation often involves blocking these pathways. For instance, myostatin promotes EMT of the dermomyotome during somitogenesis, and its inhibition would constitute negative regulation. Similarly, inflammatory cytokine signaling is counteracted by epigenetic and miRNA-mediated mechanisms.
Key Genes Involved in GO:0010719 negative regulation of epithelial to mesenchymal transition
The following genes and non-coding RNAs have been experimentally implicated in the negative regulation of epithelial to mesenchymal transition, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMYD5 | Histone methyltransferase that negatively regulates SH2B3, controlling EMT in lung cancer | Epigenetic regulator; potential target for lung cancer therapy |
| SH2B3 | Adapter protein whose negative regulation by SMYD5 affects EMT | Signaling node in lung cancer EMT |
| miR-424 | MicroRNA that regulates myofibroblast differentiation during EMT | Negative regulator of EMT in fibrosis and development |
| miR-93 | MicroRNA affecting EMT and vasculogenic mimicry in triple-negative breast cancer | Therapeutic candidate for TNBC |
| SNAI1 | Transcriptional repressor that induces EMT; its negative regulation suppresses EMT | Master EMT regulator; target for inhibition |
| E-cadherin (CDH1) | Cell adhesion protein whose maintenance opposes EMT | Epithelial marker; loss indicates EMT |
| TWIST1 | Transcription factor promoting EMT; negative regulation reduces its activity | EMT inducer; target for suppression |
| ZEB1 | Transcription factor inducing EMT; negatively regulated by miRNAs | EMT driver; miRNA targets |
| TGF-beta | Cytokine that induces EMT; negative regulators block its signaling | Pathway target for anti-EMT therapies |
| NF-kB | Inflammatory transcription factor that can induce EMT; negative regulation inhibits its activity | Link between inflammation and EMT |
| Myostatin | Growth factor that promotes EMT during somitogenesis; its inhibition is negative regulation | Developmental EMT regulator |
| Galangin (flavonoid) | Dietary compound that reverses EMT via epigenetic modulation | Nutraceutical intervention in TNBC |
| SAHA | HDAC inhibitor that, with galangin, reverses EMT | Epigenetic drug combination |
| miR-200 family | MicroRNAs that repress ZEB1/2 and inhibit EMT | Well-known negative regulators of EMT |
| miR-34 | MicroRNA that suppresses EMT by targeting SNAI1 | Tumor suppressor miRNA |
| lncRNA H19 | Long non-coding RNA that can modulate EMT; its inhibition may negatively regulate EMT | Epigenetic regulator |
| BRCA1 | DNA repair protein that can influence EMT; loss is associated with EMT | Breast cancer susceptibility gene |
| CD44 | Cell surface marker associated with mesenchymal phenotype; its downregulation opposes EMT | Cancer stem cell marker |
How Is negative regulation of epithelial to mesenchymal transition Regulated?
Negative regulation of EMT is itself controlled by multiple layers of regulation. Epigenetic mechanisms, including histone methylation by SMYD5 and histone acetylation modulated by HDAC inhibitors, directly impact the expression of EMT-related genes. MicroRNAs such as miR-424 and miR-93 provide post-transcriptional control by targeting mRNAs of EMT inducers or signaling molecules. Inflammatory cytokines can induce EMT, and their effects are counterbalanced by epigenetic silencing and miRNA-mediated repression. Additionally, developmental signals like myostatin are subject to negative regulation during somitogenesis, highlighting context-dependent control.
negative regulation of epithelial to mesenchymal transition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMYD5 | Lung cancer EMT and progression | CRISPR knockout of SMYD5 in lung cancer cell lines |
| SNAI1 | Breast cancer stem cell generation and metastasis | Knockdown or knockout of SNAI1 in breast cancer cells |
| miR-93 | Triple-negative breast cancer EMT and vasculogenic mimicry | Overexpression or inhibition of miR-93 in TNBC cells |
| miR-424 | Fibrosis and myofibroblast differentiation | miR-424 knockout or overexpression in fibroblast models |
| Myostatin | Developmental EMT during somitogenesis | Myostatin knockout in chick or mouse embryos |
Cancer metastasis and progression
Loss of negative regulation of EMT is a key step in cancer metastasis. In breast cancer, SNAI1-mediated EMT is associated with cancer stem cell properties, and its suppression reduces metastatic potential. In lung cancer, negative regulation of SH2B3 by SMYD5 controls EMT, and dysregulation of this axis promotes tumor progression. Triple-negative breast cancer cells often exhibit high EMT and vasculogenic mimicry, which can be targeted by miR-93 modulation. Epigenetic reversal of EMT by galangin and SAHA offers a therapeutic strategy.
Fibrotic diseases
EMT contributes to fibrosis by generating myofibroblasts. miR-424 regulates myofibroblast differentiation during EMT, and its dysregulation may lead to excessive fibrosis. Negative regulation of EMT is therefore critical to prevent fibrotic remodeling in organs such as kidney, liver, and lung.
Developmental disorders
During embryogenesis, EMT is essential for tissue formation, and its negative regulation ensures proper morphogenesis. Myostatin promotes EMT of the dermomyotome during somitogenesis, and failure of negative regulation can disrupt somite formation. Understanding these developmental roles provides insight into congenital anomalies.
From negative regulation of epithelial to mesenchymal transition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate EMT? | CRISPR knockout of gene X in epithelial cell lines followed by TGF-beta treatment |
| Does a point mutation in gene X affect its ability to suppress EMT? | CRISPR point mutation knock-in of the mutation in cell lines |
| Does overexpression of gene X inhibit EMT? | CRISPR activation or lentiviral overexpression of gene X |
| Does a tagged version of gene X localize correctly and interact with partners? | Knock-in of a fluorescent or epitope tag at the endogenous locus |
| Which miRNAs negatively regulate EMT? | CRISPR knockout of miRNA clusters or overexpression of miRNA mimics |
| Can epigenetic drugs reverse EMT? | Treatment of cancer cells with HDAC inhibitors and flavonoids, followed by EMT marker analysis |
How to Study the negative regulation of epithelial to mesenchymal transition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identifying EMT signature after knockout of a negative regulator |
| ChIP-seq | Histone modifications and transcription factor binding | Mapping epigenetic changes at EMT gene promoters |
| miRNA profiling | Expression levels of microRNAs | Discovering miRNAs that suppress EMT |
| Western blot | Protein levels of EMT markers | Validating E-cadherin upregulation and vimentin downregulation |
| Immunofluorescence | Cellular localization of EMT markers | Visualizing epithelial vs mesenchymal morphology |
| Transwell migration assay | Cell migratory capacity | Assessing functional suppression of EMT |
| Wound healing assay | Cell migration and wound closure | Measuring EMT-related motility |
| CRISPR screening | Genome-wide identification of negative regulators | Discovering novel suppressors of EMT |
Transcriptomic analysis (RNA-seq)
RNA sequencing measures changes in gene expression associated with EMT, such as upregulation of E-cadherin and downregulation of N-cadherin, vimentin, and fibronectin. It is used to assess the impact of negative regulators on the EMT transcriptome.
Proteomic and epigenetic profiling
Proteomics can quantify protein-level changes in EMT markers and signaling molecules. Epigenetic profiling, such as ChIP-seq for histone modifications, reveals how enzymes like SMYD5 or HDAC inhibitors affect chromatin at EMT gene loci.
MicroRNA profiling and functional assays
MicroRNA arrays or small RNA sequencing identify miRNAs that are differentially expressed during EMT. Functional assays with miRNA mimics or inhibitors validate their role in negatively regulating EMT.
Imaging and cell-based assays
Immunofluorescence for E-cadherin, vimentin, and nuclear SNAI1, as well as wound healing and transwell migration assays, directly measure EMT phenotypes and the effects of negative regulators.
How CRISPR Can Be Used to Study GO:0010719 negative regulation of epithelial to mesenchymal transition
Knockout
CRISPR knockout is used to delete candidate negative regulators of EMT, such as SMYD5 or SH2B3, to determine whether their loss enhances EMT. For example, knockout of SMYD5 in lung cancer cells can increase SH2B3 expression and affect EMT markers. Knockout of miRNA genes like miR-93 can also be performed to assess their role in suppressing EMT.
Point Mutation
Point mutations can be introduced into genes encoding negative regulators to dissect specific residues required for their function. For instance, mutating phosphorylation sites in SH2B3 or catalytic residues in SMYD5 can reveal their importance in EMT suppression. This approach helps distinguish between enzymatic activity and scaffolding functions.
Knock-in
Knock-in of reporter genes or epitope tags at endogenous loci allows real-time monitoring of negative regulator expression and localization during EMT. Tagging SMYD5 or SH2B3 with fluorescent proteins enables live-cell imaging of their dynamics. Knock-in of mutant alleles can also model disease-associated variants.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression is used to increase levels of negative regulators to test whether they are sufficient to block EMT. Overexpression of miR-424 or miR-93 can suppress mesenchymal traits in cancer cells. This approach is valuable for validating tumor suppressor-like functions.
How EDITGENE Supports negative regulation of epithelial to mesenchymal transition Research
Researchers studying negative regulation of epithelial to mesenchymal transition-related genes often need to determine whether a candidate gene is causally involved in suppressing EMT or is merely correlated with the phenotype. Functional validation through precise genome editing is essential to establish causality and to dissect molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of epithelial to mesenchymal transition research.
Frequently Asked Questions About negative regulation of epithelial to mesenchymal transition
What is GO:0010719?
GO:0010719 is the Gene Ontology term for negative regulation of epithelial to mesenchymal transition, describing any process that decreases the rate, frequency, or extent of EMT.
What genes are involved in negative regulation of epithelial to mesenchymal transition?
Key genes include SMYD5, SH2B3, SNAI1, miR-424, miR-93, and epigenetic modifiers such as HDACs.
How is negative regulation of EMT studied?
Researchers use CRISPR knockout, overexpression, RNA-seq, ChIP-seq, miRNA profiling, and cell-based assays to study this process.
Why is negative regulation of EMT important in cancer?
It prevents cancer cells from acquiring migratory and invasive properties, and its loss is associated with metastasis and poor prognosis.
What microRNAs negatively regulate EMT?
miR-424 and miR-93 are examples of microRNAs that negatively regulate EMT in fibrosis and triple-negative breast cancer, respectively.
Can epigenetic drugs reverse EMT?
Yes, compounds like galangin and SAHA have been shown to reverse EMT through epigenetic modulations in triple-negative breast cancer.
What is the role of SMYD5 in EMT?
SMYD5 negatively regulates SH2B3, and this axis controls EMT in lung cancer.
How does myostatin relate to negative regulation of EMT?
Myostatin promotes EMT during somitogenesis, so its inhibition represents a form of negative regulation.
What experimental models are used for negative regulation of EMT?
Common models include CRISPR knockout and knock-in cell lines, miRNA mimics/inhibitors, and epigenetic drug treatments.
What diseases are linked to dysregulated negative regulation of EMT?
Cancer metastasis, fibrosis, and developmental disorders are linked to loss of negative regulation of EMT.
Conclusion
Negative regulation of epithelial to mesenchymal transition (GO:0010719) is a critical biological process that safeguards against pathological EMT. Through transcriptional repression, miRNA-mediated inhibition, epigenetic silencing, and stabilization of epithelial adhesion, cells maintain their epithelial identity. Disruption of these mechanisms contributes to cancer progression, fibrosis, and developmental anomalies. Continued research using CRISPR-based models and multi-omics approaches will uncover new therapeutic targets and deepen our understanding of EMT control.
References
- 1. Markopoulos GS et al.. 2019. Epigenetic Regulation of Inflammatory Cytokine-Induced Epithelial-To-Mesenchymal Cell Transition and Cancer Stem Cell Generation.. Cells 8(10) PMID: 31557902
- 2. Tae IH et al.. 2024. Negative regulation of SH2B3 by SMYD5 controls epithelial-mesenchymal transition in lung cancer.. Mol Cells 47(5):100067 PMID: 38723947
- 3. Singh D et al.. 2021. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells.. Cell Signal 87:110151 PMID: 34537302
- 4. Nimal S et al.. 2025. Reversal of epithelial to mesenchymal transition in triple negative breast cancer through epigenetic modulations by dietary flavonoid Galangin and its combination with SAHA.. Cell Commun Signal 23(1):163 PMID: 40176095
- 5. Xiao X et al.. 2015. Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition.. Arch Biochem Biophys 566:49-57 PMID: 25524739
- 6. Zhou Y et al.. 2018. Myostatin promotes the epithelial-to-mesenchymal transition of the dermomyotome during somitogenesis.. Dev Dyn 247(12):1241-1252 PMID: 30325085
- 7. Peng F et al.. 2016. Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer.. Tumour Biol 37(11):14463-14477 PMID: 27644253
- 8. An G et al.. 2021. Effects of miR‑93 on epithelial‑to‑mesenchymal transition and vasculogenic mimicry in triple‑negative breast cancer cells.. Mol Med Rep 23(1) PMID: 33179106
